Alentis Raises $181m For Its ADCs Targeting Novel Target Claudin-1
The Swiss biotech is expanding on its Claudin-1 targeting antibodies in fibrosis by moving into Phase I with its potential first-in-class antibody drug conjugates
The Swiss biotech is expanding on its Claudin-1 targeting antibodies in fibrosis by moving into Phase I with its potential first-in-class antibody drug conjugates